Justin R. Gregg, MD
Department of Urology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2012 | Vanderbilt University School of Medicine, Nashville, TN, USA, MD, Medicine |
| 2007 | Vanderbilt University College of Arts and Science, Nashville, TN, USA, BS, Biological Sciences |
Postgraduate Training
| 2017-2019 | Clinical Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2014-2017 | Clinical Residency, Urology, Vanderbilt University Medical Center, Nashville, TN |
| 2013-2014 | Clinical Internship, General Surgery, Vanderbilt University Medical Center, Nashville, TN |
Licenses & Certifications
| 2017 | American Board of Urology |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Health Disparities Research, Division of OVP, Cancer Prevention and Population Sciences, Division of Cancer Prevention and Population Sciences, Houston, TX, 2020 - Present
Honors & Awards
| 2018 | Recipient of the William L. Pippin, Jr. Fellowship in Genitourinary Research, The University of Texas at MD Anderson Cancer Center |
| 2011 | Alpha Omega Alpha Honor Society |
| 2007 | High Honors in Biological Sciences, Vanderbilt University College of Arts and Science |
Grant & Contract Support
| Date: | 2019 - 2022 |
| Title: | Investigating the use of a plasma-based sphingolipid signature and dietary change in patients with localized prostate cancer managed with active surveillance |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | P50 CA140388 |
| Date: | 2018 - 2022 |
| Title: | DOD, CDMRP, Prostate Cancer Research Program, Early Career Investigator Award Proteomic-based Biomarkers for Risk of Progression in Early Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| ID: | PC171067 |
Selected Publications
Peer-Reviewed Articles
- Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv 3(1), 2022. e-Pub 2021. PMID: 34993496.
- Lauren Folgosa Cooley 1, Adaeze A Emeka 1, Travis J Meyers 2, Phillip R Cooper 1, Daniel W Lin 3 4, Antonio Finelli 5, James A Eastham 6, Christopher J Logothetis 7, Leonard S Marks 8, Danny Vesprini 9, S Larry Goldenberg 10, Celestia S Higano 10, Christian P Pavlovich 11, June M Chan 2 12, Todd M Morgan 13, Eric A Klein 14, Daniel A Barocas 15, Stacy Loeb 16, Brian T Helfand 17, Denise M Scholtens 18, John S Witte 2 12 19, William J Catalona. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol, 2021. e-Pub 2021. PMID: 34503355.
- Dalnim Cho, Kathrin Milbury, Yue Liao, Curtis A Pettaway, Justin R Gregg, Yisheng Li, Lorna H McNeill. Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners. PLoS One, 2021. PMID: 34370761.
- Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int 127(3):340-348, 2021. e-Pub 2020. PMID: 32357283.
- Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer 127(5):720-728, 2021. e-Pub 2021. PMID: 33411364.
- Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus 7(1):71-77, 2021. e-Pub 2019. PMID: 31076357.
- Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW. The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance. J Urol 205(1):101097JU0000000000001321, 2021. e-Pub 2020. PMID: 32718204.
- Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun 11(1):4279, 2020. e-Pub 2020. PMID: 32855410.
- Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology 138:91-97, 2020. e-Pub 2019. PMID: 31899230.
- Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CR. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer 120(4):466-471, 2019. e-Pub 2019. PMID: 30679782.
- Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance. J Urol 201(2):308-314, 2019. PMID: 30179617.
- Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol 74(2):140-143, 2018. e-Pub 2018. PMID: 29656854.
- Gregg JR, Lang M, Wang LL, Resnick MJ, Jain SK, Warner JL, Barocas DA. Automating the Determination of Prostate Cancer Risk Strata From Electronic Medical Records. JCO Clin Cancer Inform 1:1-8, 2017. e-Pub 2017. PMID: 29541700.
- Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA. Effect of Preoperative Nutritional on Mortality After Radical Cystectomy for Bladder Cancer. J Urol 185(1):90-96, 2011. e-Pub 2010. PMID: 21074802.
Invited Articles
- Gregg JR and Scarpato KR. Surgical Approaches for Open Renal Surgery, Including Open Radical Nephrectomy. Hinman’s Atlas of Urologic Surgery, 2017.
- Gregg JR and Chang SS. Treatment of muscle-invasive bladder cancer. Evidence-Based Urology. Wiley, 2017.
- Gregg JR and Chang SS. Blue-light and Narrow Band Imaging in the Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. AUA Update Series, 2017.
- Gregg JR, Dahm P, Chang SS. Guideline-based management of non-muscle invasive bladder cancer. Indian J Urol 31(4):320-326, 2015. PMID: 26604443.
Patient Reviews
CV information above last modified August 08, 2024